Cargando…

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Detalles Bibliográficos
Autores principales:	Heuser, Michael, Smith, B. Douglas, Fiedler, Walter, Sekeres, Mikkael A., Montesinos, Pau, Leber, Brian, Merchant, Akil, Papayannidis, Cristina, Pérez-Simón, José A., Hoang, Caroline J., O’Brien, Thomas, Ma, Weidong Wendy, Zeremski, Mirjana, O’Connell, Ashleigh, Chan, Geoffrey, Cortes, Jorge E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496603/ https://www.ncbi.nlm.nih.gov/pubmed/33978823 http://dx.doi.org/10.1007/s00277-021-04545-5

Ejemplares similares

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
por: Heuser, Michael, et al.
Publicado: (2021)

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
por: Cortes, Jorge E., et al.
Publicado: (2020)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Cortes, Jorge E., et al.
Publicado: (2018)

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
por: Sekeres, Mikkael A., et al.
Publicado: (2023)

Cytarabine/glasdegib: COVID-19 infection and CNS haemorrhage: 2 case reports
Publicado: (2021)

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists
por: Relias, Valerie, et al.
Publicado: (2020)

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021)

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy
por: Solem, Caitlyn T., et al.
Publicado: (2020)

Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
por: Ruiz‐Garcia, Ana, et al.
Publicado: (2020)

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2019)

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
por: Lin, Swan, et al.
Publicado: (2019)

Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
por: Thompson, Daniel L., et al.
Publicado: (2020)

Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
por: Shaik, Naveed, et al.
Publicado: (2021)

Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue
por: Peklar, Boris, et al.
Publicado: (2022)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
por: Lin, Swan, et al.
Publicado: (2020)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies
por: Minami, Yosuke, et al.
Publicado: (2017)

Clinical and Model‐Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Cytarabine-Induced Encephalitis
por: Lenfant, Christine, et al.
Publicado: (2021)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Rational design of a new cytarabine-based prodrug for highly efficient oral delivery of cytarabine
por: Zhang, Jing, et al.
Publicado: (2018)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study
por: Masters, Joanna C., et al.
Publicado: (2020)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

A novel cytarabine crystalline lipid prodrug: Hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy
por: Kim, Jae Suk, et al.
Publicado: (2012)

NxRepair: error correction in de novo sequence assembly using Nextera mate pairs
por: Murphy, Rebecca R., et al.
Publicado: (2015)

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018)

Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy
por: Lewicky, Jordan D., et al.
Publicado: (2022)

Synergistic interactions of cytarabine-adavosertib in leukemic cell lines proliferation and metabolomic endpoints
por: Rodríguez-Vázquez, Gabriel O., et al.
Publicado: (2023)

Cytarabine-Induced Bradycardia: A Case Report
por: Albsheer, Khalid, et al.
Publicado: (2022)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Nucleoside transporter-guided cytarabine-conjugated liposomes for intracellular methotrexate delivery and cooperative choriocarcinoma therapy
por: Fei, Weidong, et al.
Publicado: (2021)

The bioavailability of cytarabine in dogs with meningoencephalitis of unknown etiology through iontophoresis and rectal delivery
por: Mancini, Shelby L., et al.
Publicado: (2021)

Understanding and working with different worldviews to co-design cultural security in clinical mental health settings to engage with Aboriginal and Torres Strait Islander clients
por: Wright, Michael, et al.
Publicado: (2021)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
por: Zeidner, Joshua F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r9ubjuq7bo6vv96vkl12o8sf6q